{
    "clinical_study": {
        "@rank": "92424", 
        "acronym": "GINI", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "description": "HPV vaccination regime-standard 3-dose needle injection IM regimen"
            }, 
            {
                "arm_group_label": "Group II", 
                "description": "HPV vaccination regime-3-dose needle-free (NFI) IM injection regimen"
            }, 
            {
                "arm_group_label": "Group III", 
                "description": "HPV vaccination regime - 3-dose needle-free intradermal injection regimen"
            }
        ], 
        "brief_summary": {
            "textblock": "In collaboration with the Thai Red Cross AIDS Research Centre, the investigators are\n      performing a study of 2 new HPV vaccine delivery regimens in healthy young Thai women.  The\n      study will be performed in Bangkok.  The investigators will be testing the serum from these\n      women at UCSF for HPV antibodies to measure the strength of their response to the vaccine."
        }, 
        "brief_title": "Gardasil Immunogenicity With Needle-Free Injection", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "HPV Seroconversion", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Thai women age 18-26 years\n\n          -  no more than 5 lifetime partners\n\n          -  HIV-uninfected\n\n          -  no history of HPV vaccination\n\n          -  judged able to complete all of the protocol visits\n\n          -  no contraindications to vaccination with Gardasil\n\n        Exclusion Criteria:\n\n        -  Does not satisfy all of the inclusion criteria"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "26 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The study is only for women; the study is focused on the safety and immunogenicity of the\n        HPV vaccine in women.  Separate studies will be done in men if the dosing regimens in\n        Groups II or III are shown to be non-inferior to the standard regimen."
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01924754", 
            "org_study_id": "GINI"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "HPV", 
            "Gardasil", 
            "seroconversion"
        ], 
        "lastchanged_date": "April 8, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jpalefsky@medicine.ucsf.edu", 
                    "last_name": "Joel Palefsky, MD", 
                    "phone": "415-476-1574"
                }, 
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94062"
                    }, 
                    "name": "University of California, San Francisco"
                }, 
                "investigator": {
                    "last_name": "Joel Palefsky, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "nittaya.p@trcarc.org", 
                    "last_name": "Nittaya Phanuphak, MD"
                }, 
                "contact_backup": {
                    "email": "siriporn.n@searchthailand.org", 
                    "last_name": "Siriporn NSiriporn Nonenoy"
                }, 
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand"
                    }, 
                    "name": "Thai Red Cross AIDS Research Centre"
                }, 
                "investigator": {
                    "last_name": "Nittaya Phanuphak, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Thailand"
            ]
        }, 
        "number_of_groups": "3", 
        "official_title": "Gardasil Immunogenicity With Needle-Free Injection", 
        "overall_official": {
            "affiliation": "University of California, San Francisco", 
            "last_name": "Joel Palefsky, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Compare rates of seroconversion and geometric mean titers (GMTs) generated following a 3-dose series of vaccine in women given low doses of vaccine by the intradermal (ID) route with the needle-free injector (NFI) (Group III) to those women given standard doses by the intramuscular (IM) route with a needle and syringe (Group I) at 1 month, 6 months and 12 months following completion of the vaccination series.", 
                "measure": "Seroconversion Group III vs Group I", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Compare rates of seroconversion and GMTs generated following a 3-dose series of vaccine in women given standard doses of vaccine by the IM route with the NFI (Group II) to those women given standard doses by the IM route with a needle and syringe (Group I) at 1 month, 6 months and 12 months following completion of the vaccination series.", 
                "measure": "Seroconversion Group II vs Group I", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01924754"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}